Skip to main content
Premium Trial:

Request an Annual Quote

Premier Biosoft Buys Redasoft to Expand Life Science Customer Base


Premier Biosoft has acquired privately held bioinformatics company Redasoft in an effort to expand its life sciences software business.

Redasoft markets sequence analysis software dubbed Visual Cloning, which includes vector map drawing capabilities and lets users create graphical maps based on sequence data. It also provides tools for restriction site analysis as well as to search for open reading frames.

Palo Alto, Calif.-based Premier, which is also privately held, expects the new acquisition to expand its reach in the life science software market.

“The acquisition of Redasoft demonstrates our strategy to strengthen our presence in the life science sector and deliver sustainable ... growth by offering a wide portfolio of products and services,” Kay Brown, Premier's president, said in a statement.

Premier offers software products and services for PCR and real time PCR, cloning, DNA and tissue microarrays, suspension bead arrays, glycomics, and mutagenesis. Its primary customers are government agencies, pharmaceutical and biotechnology companies, and academic researchers.

Additional details about the acquisition were not provided.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.